Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

A Molecular Diagnostic Algorithm to Guide Pollen Immunotherapy in Southern Europe: Towards Component-Resolved Management of Allergic Diseases

Douladiris N. · Savvatianos S. · Roumpedaki I. · Skevaki C. · Mitsias D. · Papadopoulos N.G.

Author affiliations

Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece

Related Articles for ""

Int Arch Allergy Immunol 2013;162:163-172

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 20, 2013
Accepted: May 17, 2013
Published online: July 31, 2013
Issue release date: September 2013

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

Correct identification of the culprit allergen is an essential part of diagnosis and treatment in immunoglobulin E (IgE)-mediated allergic diseases. In recent years, molecular biology has made important advances facilitating such identification and overcoming some of the drawbacks of natural allergen extracts, which consist of mixtures of various proteins that may be allergenic or not, specific for the allergen source or widely distributed (panallergens). New technologies offer the opportunity for a more accurate component-resolved diagnosis, of benefit especially to polysensitized allergic patients. The basic elements of molecular diagnostics with potential relevance to immunotherapy prescription are reviewed here, with a focus on Southern European sensitization patterns to pollen allergens. We propose a basic algorithm regarding component-resolved diagnostic work-up for pollen allergen-specific immunotherapy candidates in Southern Europe; this and similar algorithms can form the basis of improved patient management, conceptually a ‘Component-Resolved Allergy Management'.

© 2013 S. Karger AG, Basel


References

  1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(suppl 86):8-160.
  2. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478.
  3. Woodcock A, Lowe LA, Murray CS, Simpson BM, Pipis SD, Kissen P, Simpson A, Custovic A: Early life environmental control: effect on symptoms, sensitization, and lung function at age 3 years. Am J Respir Crit Care Med 2004;170:433-439.
  4. Custovic A, Wijk RG: The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy 2005;60:1112-1115.
  5. Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, Le Souef P, Makela M, Roberts G, Wong G, Zar H, Akdis CA, Bacharier LB, Baraldi E, van Bever HP, de Blic J, Boner A, Burks W, Casale TB, Castro-Rodriguez JA, Chen YZ, El-Gamal YM, Everard ML, Frischer T, Geller M, Gereda J, Goh DY, Guilbert TW, Hedlin G, Heymann PW, Hong SJ, Hossny EM, Huang JL, Jackson DJ, de Jongste JC, Kalayci O, Ait-Khaled N, Kling S, Kuna P, Lau S, Ledford DK, Lee SI, Liu AH, Lockey RF, Lodrup-Carlsen K, Lotvall J, Morikawa A, Nieto A, Paramesh H, Pawankar R, Pohunek P, Pongracic J, Price D, Robertson C, Rosario N, Rossenwasser LJ, Sly PD, Stein R, Stick S, Szefler S, Taussig LM, Valovirta E, Vichyanond P, Wallace D, Weinberg E, Wennergren G, Wildhaber J, Zeiger RS: International consensus on (ICON) pediatric asthma. Allergy 2012;67:976-997.
  6. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475.
  7. Eng PA, Reinhold M, Gnehm HP: Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306-312.
  8. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Moller C: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-948.
  9. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-1397.
  10. Dreborg S, Lee TH, Kay AB, Durham SR: Immunotherapy is allergen-specific: a double-blind trial of mite or Timothy extract in mite and grass dual-allergic patients. Int Arch Allergy Immunol 2012;158:63-70.
  11. Larenas-Linnemann D, Esch RE, Guidos-Fogelbach G, Rodriguez-Perez N: A comparison of in vitro potency between European and Mexican allergen extracts and US (CBER/FDA) reference extracts. Allergol Immunopathol (Madr) 2010;38:170-173.
  12. Larenas-Linnemann D, Cox LS: European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol 2008;100:137-145.
  13. Larenas-Linnemann D, Esch R, Plunkett G, Brown S, Maddox D, Barnes C, Constable D: Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann Allergy Asthma Immunol 2011;107:448-458 e443.
  14. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H: The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999;29:896-904.
  15. Valenta R, Twaroch T, Swoboda I: Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. J Investig Allergol Clin Immunol 2007;17(suppl 1):36-40.
    External Resources
  16. Asero R: Component-resolved diagnosis-assisted prescription of allergen-specific immunotherapy: a practical guide. Eur Ann Allergy Clin Immunol 2012;44:183-187.
    External Resources
  17. Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F, Kraft D, Valenta R: Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004;34:597-603.
  18. Schmid-Grendelmeier P: Recombinant allergens. For routine use or still only science? Hautarzt 2010;61:946-953.
  19. European Declaration on Allergen Immunotherapy. European Academy of Allergy and Clinical Immunology, 2011. Available from eaaci.net.
  20. Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R: Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol 2002;127:259-268.
  21. Niederberger V, Laffer S, Froschl R, Kraft D, Rumpold H, Kapiotis S, Valenta R, Spitzauer S: IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 1998;101:258-264.
  22. Johansen N, Weber RW, Ipsen H, Barber D, Broge L, Hejl C: Extensive IgE cross-reactivity towards the Pooideae grasses substantiated for a large number of grass-pollen-sensitized subjects. Int Arch Allergy Immunol 2009;150:325-334.
  23. Hejl C, Wurtzen PA, Kleine-Tebbe J, Johansen N, Broge L, Ipsen H: Phleum pratense alone is sufficient for allergen-specific immunotherapy against allergy to Pooideae grass pollens. Clin Exp Allergy 2009;39:752-759.
  24. Moingeon P, Hrabina M, Bergmann KC, Jaeger S, Frati F, Bordas V, Peltre G: Specific immunotherapy for common grass pollen allergies: pertinence of a five-grass pollen vaccine. Int Arch Allergy Immunol 2008;146:338-342.
  25. Chabre H, Gouyon B, Huet A, Baron-Bodo V, Nony E, Hrabina M, Fenaille F, Lautrette A, Bonvalet M, Maillere B, Bordas-Le Floch V, Van Overtvelt L, Jain K, Ezan E, Batard T, Moingeon P: Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy. Clin Exp Allergy 2010;40:505-519.
  26. Andersson K, Lidholm J: Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 2003;130:87-107.
  27. Tripodi S, Frediani T, Lucarelli S, Macri F, Pingitore G, Di Rienzo Businco A, Dondi A, Pansa P, Ragusa G, Asero R, Faggian D, Plebani M, Matricardi PM: Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. J Allergy Clin Immunol 2012;129:834-839 e838.
  28. Duffort O, Quintana J, Ipsen H, Barber D, Polo F: Antigenic similarity among group 1 allergens from grasses and quantitation ELISA using monoclonal antibodies to Phl p 1. Int Arch Allergy Immunol 2008;145:283-290.
  29. Sastre J: Molecular diagnosis in allergy. Clin Exp Allergy 2010;40:1442-1460.
  30. Calderon MA, Larenas D, Kleine-Tebbe J, Jacobsen L, Passalacqua G, Eng PA, Varga EM, Valovirta E, Moreno C, Malling HJ, Alvarez-Cuesta E, Durham S, Demoly P: European Academy of Allergy and Clinical Immunology Task Force report on ‘dose-response relationship in allergen-specific immunotherapy'. Allergy 2011;66:1345-1359.
  31. Sander I, Fleischer C, Meurer U, Bruning T, Raulf-Heimsoth M: Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy 2009;64:1486-1492.
  32. Schmidt H, Gelhaus C, Nebendahl M, Janssen O, Petersen A: Characterization of Phleum pratense pollen extracts by 2-D DIGE and allergen immunoreactivity. Proteomics 2010;10:4352-4362.
  33. Quiralte J, Palacios L, Rodriguez R, Cardaba B, Arias de Saavedra JM, Villalba M, Florido JF, Lahoz C: Modelling diseases: the allergens of Olea europaea pollen. J Investig Allergol Clin Immunol 2007;17(suppl 1):24-30.
    External Resources
  34. Barber D, Moreno C, Ledesma A, Serrano P, Galan A, Villalba M, Guerra F, Lombardero M, Rodriguez R: Degree of olive pollen exposure and sensitization patterns. Clinical implications. J Investig Allergol Clin Immunol 2007;17(suppl 1):11-16.
    External Resources
  35. Lombardero M, Obispo T, Calabozo B, Lezaun A, Polo F, Barber D: Cross-reactivity between olive and other species. Role of Ole e 1-related proteins. Allergy 2002;57(suppl 71):29-34.
  36. Rodriguez R, Villalba M, Batanero E, Palomares O, Quiralte J, Salamanca G, Sirvent S, Castro L, Prado N: Olive pollen recombinant allergens: value in diagnosis and immunotherapy. J Investig Allergol Clin Immunol 2007;17(suppl 1):4-10.
    External Resources
  37. Asero R: Analysis of hypersensitivity to oleaceae pollen in an olive-free and ash-free area by commercial pollen extracts and recombinant allergens. Eur Ann Allergy Clin Immunol 2011;43:77-80.
    External Resources
  38. Palomares O, Swoboda I, Villalba M, Balic N, Spitzauer S, Rodriguez R, Valenta R: The major allergen of olive pollen Ole e 1 is a diagnostic marker for sensitization to Oleaceae. Int Arch Allergy Immunol 2006;141:110-118.
  39. Aceituno E, Del Pozo V, Minguez A, Arrieta I, Cortegano I, Cardaba B, Gallardo S, Rojo M, Palomino P, Lahoz C: Molecular cloning of major allergen from Cupressus arizonica pollen: Cup a 1. Clin Exp Allergy 2000;30:1750-1758.
  40. Charpin D, Gouitaa M, Dron-Gonzalvez M, Fardeau MF, Massabie-Bouchat YP, Hugues B, Fabre C, Vivinus S, Pegliasco H, Andre C: Immunotherapy with an aluminum hydroxide-adsorbed Juniperus ashei foreign pollen extract in seasonal indigenous cypress pollen rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007;143:83-91.
  41. Asturias JA, Ibarrola I, Bartolome B, Ojeda I, Malet A, Martinez A: Purification and characterization of Pla a 1, a major allergen from Platanus acerifolia pollen. Allergy 2002;57:221-227.
  42. Ibarrola I, Arilla MC, Martinez A, Asturias JA: Identification of a polygalacturonase as a major allergen (Pla a 2) from Platanus acerifolia pollen. J Allergy Clin Immunol 2004;113:1185-1191.
  43. Lauer I, Miguel-Moncin MS, Abel T, Foetisch K, Hartz C, Fortunato D, Cistero-Bahima A, Vieths S, Scheurer S: Identification of a plane pollen lipid transfer protein (Pla a 3) and its immunological relation to the peach lipid-transfer protein, Pru p 3. Clin Exp Allergy 2007;37:261-269.
  44. D'Amato G, Liccardi G: Pollen-related allergy in the European Mediterranean area. Clin Exp Allergy 1994;24:210-219.
  45. D'Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, Liccardi G, Popov T, van Cauwenberge P: Allergenic pollen and pollen allergy in Europe. Allergy 2007;62:976-990.
  46. Barber D, de la Torre F, Feo F, Florido F, Guardia P, Moreno C, Quiralte J, Lombardero M, Villalba M, Salcedo G, Rodriguez R: Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy 2008;63:1550-1558.
  47. Asturias JA, Gomez-Bayon N, Eseverri JL, Martinez A: Par j 1 and Par j 2, the major allergens from Parietaria judaica pollen, have similar immunoglobulin E epitopes. Clin Exp Allergy 2003;33:518-524.
  48. Stumvoll S, Westritschnig K, Lidholm J, Spitzauer S, Colombo P, Duro G, Kraft D, Geraci D, Valenta R: Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J Allergy Clin Immunol 2003;111:974-979.
  49. Tordesillas L, Sirvent S, Diaz-Perales A, Villalba M, Cuesta-Herranz J, Rodriguez R, Salcedo G: Plant lipid transfer protein allergens: no cross-reactivity between those from foods and olive and Parietaria pollen. Int Arch Allergy Immunol 2011;156:291-296.
  50. Salcedo G, Sanchez-Monge R, Barber D, Diaz-Perales A: Plant non-specific lipid transfer proteins: an interface between plant defence and human allergy. Biochim Biophys Acta 2007;1771:781-791.
  51. Gadermaier G, Harrer A, Girbl T, Palazzo P, Himly M, Vogel L, Briza P, Mari A, Ferreira F: Isoform identification and characterization of Art v 3, the lipid-transfer protein of mugwort pollen. Mol Immunol 2009;46:1919-1924.
  52. Rossi RE, Monasterolo G, Coco G, Operti D: Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component-resolved diagnosis. Int Arch Allergy Immunol 2005;138:105-110.
  53. Pastorello EA, Pravettoni V, Farioli L, Rivolta F, Conti A, Ispano M, Fortunato D, Bengtsson A, Bianchi M: Hypersensitivity to mugwort (Artemisia vulgaris) in patients with peach allergy is due to a common lipid transfer protein allergen and is often without clinical expression. J Allergy Clin Immunol 2002;110:310-317.
  54. Pascal M, Munoz-Cano R, Reina Z, Palacin A, Vilella R, Picado C, Juan M, Sanchez-Lopez J, Rueda M, Salcedo G, Valero A, Yague J, Bartra J: Lipid transfer protein syndrome: clinical pattern, cofactor effect and profile of molecular sensitization to plant foods and pollens. Clin Exp Allergy 2012;42:1529-1539.
  55. Asero R, Pravettoni V: Anaphylaxis to plant foods and pollen allergens in patients with lipid transfer protein syndrome. Curr Opin Allergy Clin Immunol 2013, E-pub ahead of print.
  56. Asero R: Co-recognition of lipid trasfer protein in pollen and foods in northern Italy: clinician's view. Eur Ann Allergy Clin Immunol 2010;42:205-208.
    External Resources
  57. Gao ZS, Yang ZW, Wu SD, Wang HY, Liu ML, Mao WL, Wang J, Gadermaier G, Ferreira F, Zheng M, van Ree R: Peach allergy in China: a dominant role for mugwort pollen lipid transfer protein as a primary sensitizer. J Allergy Clin Immunol 2013;131:224-226 e223.
  58. Lombardero M, Garcia-Selles FJ, Polo F, Jimeno L, Chamorro MJ, Garcia-Casado G, Sanchez-Monge R, Diaz-Perales A, Salcedo G, Barber D: Prevalence of sensitization to Artemisia allergens Art v 1, Art v 3 and Art v 60 kDa. Cross-reactivity among Art v 3 and other relevant lipid-transfer protein allergens. Clin Exp Allergy 2004;34:1415-1421.
  59. Oberhuber C, Ma Y, Wopfner N, Gadermaier G, Dedic A, Niggemann B, Maderegger B, Gruber P, Ferreira F, Scheiner O, Hoffmann-Sommergruber K: Prevalence of IgE-binding to Art v 1, Art v 4 and Amb a 1 in mugwort-allergic patients. Int Arch Allergy Immunol 2008;145:94-101.
  60. Gadermaier G, Wopfner N, Wallner M, Egger M, Didierlaurent A, Regl G, Aberger F, Lang R, Ferreira F, Hawranek T: Array-based profiling of ragweed and mugwort pollen allergens. Allergy 2008;63:1543-1549.
  61. Leonard R, Wopfner N, Pabst M, Stadlmann J, Petersen BO, Duus JO, Himly M, Radauer C, Gadermaier G, Razzazi-Fazeli E, Ferreira F, Altmann F: A new allergen from ragweed (Ambrosia artemisiifolia) with homology to art v 1 from mugwort. J Biol Chem 2010;285:27192-27200.
  62. Arilla MC, Ibarrola I, Brena S, Martinez A, Colas C, Asturias JA: The Russian thistle (Salsola kali) pollen major allergen, Sal k 1, can be quantified in allergenic extracts and airborne pollen. Int Arch Allergy Immunol 2010;152:319-326.
  63. Barderas R, Garcia-Selles J, Salamanca G, Colas C, Barber D, Rodriguez R, Villalba M: A pectin methylesterase as an allergenic marker for the sensitization to Russian thistle (Salsola kali) pollen. Clin Exp Allergy 2007;37:1111-1119.
  64. Hauser M, Roulias A, Ferreira F, Egger M: Panallergens and their impact on the allergic patient. Allergy Asthma Clin Immunol 2010;6:1.
  65. Barber D, de la Torre F, Lombardero M, Antépara I, Colas C, Dávila I, Tabar AI, Vidal C, Villalba M, Salcedo G, Rodríguez R: Component-resolved diagnosis of pollen allergy based on skin testing with profilin, polcalcin and lipid transfer protein pan-allergens. Clin Exp Allergy 2009;39:1764-1773.
  66. Villalta D, Asero R: Analysis of the allergenic profile of patients hypersensitive to pollen pan-allergens living in two distinct areas of northern Italy. Eur Ann Allergy Clin Immunol 2011;43:54-57.
    External Resources
  67. Mari A: Multiple pollen sensitization: a molecular approach to the diagnosis. Int Arch Allergy Immunol 2001;125:57-65.
  68. Asero R, Monsalve R, Barber D: Profilin sensitization detected in the office by skin prick test: a study of prevalence and clinical relevance of profilin as a plant-food allergen. Clin Exp Allergy 2008;38:1033-1037.
  69. Asero R, Mistrello G, Roncarolo D, Amato S: Parietaria profilin shows only limited cross-reactivity with birch and grass profilins. Int Arch Allergy Immunol 2004;133:121-124.
  70. Santos A, Van Ree R: Profilins: mimickers of allergy or relevant allergens? Int Arch Allergy Immunol 2011;155:191-204.
  71. Grote M, Westritschnig K, Valenta R: Immunogold electron microscopic localization of the 2 EF-hand calcium-binding pollen allergen Phl p 7 and its homologues in pollens of grasses, weeds and trees. Int Arch Allergy Immunol 2008;146:113-121.
  72. Ledesma A, Barderas R, Westritschnig K, Quiralte J, Pascual CY, Valenta R, Villalba M, Rodriguez R: A comparative analysis of the cross-reactivity in the polcalcin family including Syr v 3, a new member from lilac pollen. Allergy 2006;61:477-484.
  73. Tinghino R, Twardosz A, Barletta B, Puggioni EMR, Iacovacci P, Butteroni C, Afferni C, Mari A, Hayek B, Di Felice G, Focke M, Westritschnig K, Valenta R, Pini C: Molecular, structural, and immunologic relationships between different families of recombinant calcium-binding pollen allergens. J Allergy Clin Immunol 2002;109:314-320.
  74. Ruiz-Garcia M, Garcia Del Potro M, Fernandez-Nieto M, Barber D, Jimeno-Nogales L, Sastre J: Profilin: a relevant aeroallergen? J Allergy Clin Immunol 2011;128:416-418.
  75. Asero R, Jimeno L, Barber D: Preliminary results of a skin prick test-based study of the prevalence and clinical impact of hypersensitivity to pollen panallergens (polcalcin and profilin). J Investig Allergol Clin Immunol 2010;20:35-38.
    External Resources
  76. Nunez R, Carballada F, Lombardero M, Jimeno L, Boquete M: Profilin as an aeroallergen by means of conjunctival allergen challenge with purified date palm profilin. Int Arch Allergy Immunol 2012;158:115-119.
  77. Hatzler L, Panetta V, Lau S, Wagner P, Bergmann RL, Illi S, Bergmann KE, Keil T, Hofmaier S, Rohrbach A, Bauer CP, Hoffman U, Forster J, Zepp F, Schuster A, Wahn U, Matricardi PM: Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol 2012;130:894-901 e895.
  78. Mari A: Skin test with a Timothy grass (Phleum pratense) pollen extract vs. IgE to a Timothy extract vs. IgE to rPhl p 1, rPhl p 2, nPhl p 4, rPhl p 5, rPhl p 6, rPhl p 7, rPhl p 11, and rPhl p 12: epidemiological and diagnostic data. Clin Exp Allergy 2003;33:43-51.
  79. Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446-453.
  80. Altmann F: The role of protein glycosylation in allergy. Int Arch Allergy Immunol 2007;142:99-115.
  81. Mari A, Ooievaar-de Heer P, Scala E, Giani M, Pirrotta L, Zuidmeer L, Bethell D, van Ree R: Evaluation by double-blind placebo-controlled oral challenge of the clinical relevance of IgE antibodies against plant glycans. Allergy 2008;63:891-896.
  82. Malandain H, Giroux F, Cano Y: The influence of carbohydrate structures present in common allergen sources on specific IgE results. Eur Ann Allergy Clin Immunol 2007;39:216-220.
    External Resources
  83. Demain AL, Vaishnav P: Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009;27:297-306.
  84. Leonard R, Petersen BO, Himly M, Kaar W, Wopfner N, Kolarich D, van Ree R, Ebner C, Duus JO, Ferreira F, Altmann F: Two novel types of O-glycans on the mugwort pollen allergen Art v 1 and their role in antibody binding. J Biol Chem 2005;280:7932-7940.
  85. Sastre J, Landivar ME, Ruiz-Garcia M, Andregnette-Rosigno MV, Mahillo I: How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy 2012;67:709-711.
  86. Larenas-Linnemann D, Cruz AA, Gutierrez IR, Rodriguez P, Shah-Hosseini K, Michels A, Mosges R: European and Mexican vs. US diagnostic extracts of Bermuda grass and cat in skin testing. Ann Allergy Asthma Immunol 2011;106:421-428.
  87. Duffort O, Palomares O, Lombardero M, Villalba M, Barber D, Rodriguez R, Polo F: Variability of Ole e 9 allergen in olive pollen extracts: relevance of minor allergens in immunotherapy treatments. Int Arch Allergy Immunol 2006;140:131-138.
  88. Casset A, Mari A, Purohit A, Resch Y, Weghofer M, Ferrara R, Thomas WR, Alessandri C, Chen KW, de Blay F, Valenta R, Vrtala S: Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol 2012;159:253-262.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 20, 2013
Accepted: May 17, 2013
Published online: July 31, 2013
Issue release date: September 2013

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.